<DOC>
	<DOCNO>NCT02456883</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics 14C-labeled gilteritinib , particular , rout excretion extent metabolism gilteritinib follow administration single dose 14C-labeled gilteritinib repeat dos gilteritinib . This study also evaluate safety repeat oral administration gilteritinib subject advance solid tumor well identify metabolic profile gilteritinib plasma , urine feces single oral dose 14C-labeled gilteritinib .</brief_summary>
	<brief_title>Study Investigate Absorption , Metabolism Excretion 14C ASP2215 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Participants admit evaluation clinical research unit day 14 potentially 14 day ( day 29 ) . At approximately day 36 45 participant return clinic ( 3 day ) additional sample collection .</detailed_description>
	<criteria>Subject histologically cytologically confirm diagnosis advance solid tumor ( measurable nonmeasurable disease ) standard therapy available . Subject must Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 . Subject must life expectancy &gt; 12 week . Subject must recover effect prior systemic antineoplastic radiation therapy ( ) ≤ Grade 1 ( National Cancer Institute Common Terminology Criteria Adverse Events [ NCICTCAE ] , Version 4.0 ) severity subject 's baseline value , exclude alopecia . Subject adequate bone marrow , renal hepatic function baseline , demonstrate following : Absolute neutrophil count ( ANC ) ≥ 1500 cells/mm3 Platelet count ≥ 100,000 cells/mm3 Hemoglobin ( Hb ) ≥ 9 g/dL Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) calculate creatinine clearance &gt; 60 mL/min serum creatinine &gt; 1.5 x ULN Total bilirubin ≤ 1.5 x ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN ( &lt; 5 x ULN subject liver metastasis hepatocellular carcinoma ) . Female subject must either : Be nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior screen , document surgically sterile Or , childbearing potential : agree try become pregnant study 60 day final study drug administration negative serum urine pregnancy test screening , heterosexually active , agree consistently use 2 form birth control ( least one must barrier method ) start screen throughout study period 60 day final study drug administration . Female subject must breastfeed screen study period , 60 day final study drug administration . Female subject must donate ovum start screen throughout study period 60 day final study drug administration . Male subject female spouse/partner childbearing potential must use highly effective contraception consist 2 form birth control ( one must barrier method ) start screen continue throughout study period 120 day final study drug administration . Male subject must donate sperm start screen throughout study period 120 day final study drug administration . Subject must willing comply procedure assessment . Subject receive 5 prior cytotoxic agentcontaining regimen . Subject symptomatic central nervous system ( CNS ) metastases leptomeningeal involvement assess medical history review physical examination . Subject prior brain metastasis must : stable neurologic status post administration local therapy ( surgery radiation ) minimum 2 week follow completion definitive therapy . without neurologic dysfunction would confound evaluation neurologic adverse event ( AEs ) . Subject major surgery within 4 week prior first study dose . Subject chemotherapy within 4 week prior first study dose . Subject radiation therapy within 4 week prior first study dose . Subject know hepatitis B surface antigen ( HBsAg ) positive status ; know suspect active hepatitis C infection ; know human immunodeficiency virus ( HIV ) positive . Subject malabsorption syndrome disease condition significantly affect gastrointestinal function . Subject significant uncontrolled cardiac , renal , hepatic systemic disorder ; significant psychological condition baseline investigator 's opinion , make subject unsuitable study participation . Subject electrocardiogram ( ECG ) abnormalities 12lead ECG perform within 14 day start study drug consider Investigator clinically significant . Subject receive strong moderate inhibitor ( e.g. , ketoconazole fluconazole ) inducer ( e.g. , rifampin phenytoin ) cytochrome P450 ( CYP ) 3A4 Pglycoprotein ( Pgp ) , substrates multidrug toxin extrusion ( MATE ) 1 exception antibiotic , antifungal , antiviral use standard care post transplant prevent treat infection drug consider absolutely essential care subject within 2 week prior start study treatment study . Subject require treatment concomitant drug target serotonin 5HT1R 5HT2BR receptor sigma nonspecific receptor , exception drug consider absolutely essential care subject . Subject participate interventional clinical study treat investigational drug within 30 day 5 halflives , whichever longer , prior initiation screening . Subject known history serious hypersensitivity ASP2215 , component formulation use . Subject ongoing toxicity ≥ Grade 2 ( Common Terminology Criteria Adverse Event [ CTCAE ] v4.03 ) attributable prior medication treat solid tumor ( except alopecia ) time screen . Subject follow within 14 day prior first dose study drug : blood transfusion hemopoietic factor therapy evidence active infection require systemic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASP2215</keyword>
	<keyword>14C-labeled gilteritinib</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>gilteritinib</keyword>
</DOC>